Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs Bon Health

AbundRX
Graded #181

Lower grade

vs+3.1000000000000085
Bon Health
Graded #113

Higher grade

The verdict

Bon Health takes it — 69.7/100 to 66.6/100.

Bon Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bon Health is a physician-led GLP-1 weight-loss telehealth service selling compounded semaglutide and tirzepatide on commitment tiers.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBon Health +8
67
75
Dose & formulationEven
64
64
Clinical oversightBon Health +6
79
85
Labs & monitoringBon Health +2
53
55
FulfillmentAbundRX +2
74
72
Contract termsAbundRX +2
55
53
AbundRX · left barBon Health · right bar

The numbers

MetricAbundRXBon Health
WeighScore66.6/10069.7/100
GradeCC
Scorecard rank#181#113
Semaglutide$179/mo (compounded)$120/mo (12-month plan, compounded)
Tirzepatide$279/mo (compounded)$170/mo (12-month plan, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AbundRX

Graded #181 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Bon Health

Graded #113 · C

Strengths

  • Transparent commitment-tier pricing from $170/mo (annual) for compounded semaglutide and tirzepatide; $0 membership fee, cancel anytime
  • Physician-led: comprehensive medical review and physician-titrated dosing, not a 2-minute quiz
  • 24/7 physician support included free with your order; 1-3 day rapid dispatch
  • Licensed in all 50 states; uses 503A & 503B compounding pharmacies; brand-name Wegovy/Ozempic/Zepbound/Mounjaro also offered

Where it loses points

  • The advertised rates need a full year paid up front; billed monthly, semaglutide is $230 and the annual figure nearly doubles
  • The brand-name pages are marketing, not products — every Wegovy, Ozempic, Zepbound and Mounjaro CTA reads 'Coming Soon' and points back to the compounded version
  • Coverage is not published: a badge claims all 50 states while the weight-loss page says availability varies by state
  • The terms page returns a 404, so the refund mechanics behind the prepaid 3-, 6- and 12-month tiers cannot be read
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard